VolitionRX (NYSEAMERICAN:VNRX) Shares to Reverse Split on Tuesday, April 28th

VolitionRX Limited (NYSEAMERICAN:VNRX) shares are going to reverse split on the morning of Tuesday, April 28th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, April 27th.

VolitionRX Stock Performance

Shares of NYSEAMERICAN VNRX traded down $0.02 during midday trading on Monday, hitting $0.16. The company’s stock had a trading volume of 2,461,723 shares, compared to its average volume of 9,794,742. VolitionRX has a 1-year low of $0.15 and a 1-year high of $0.94. The firm’s fifty day moving average price is $0.20 and its 200-day moving average price is $0.29. The firm has a market cap of $25.86 million, a P/E ratio of -0.74 and a beta of 1.33.

VolitionRX (NYSEAMERICAN:VNRX) last announced its quarterly earnings data on Tuesday, March 31st. The medical research company reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05). The business had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.71 million. As a group, research analysts predict that VolitionRX will post -0.11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on VNRX. D. Boral Capital reiterated a “hold” rating on shares of VolitionRX in a research report on Monday. Citigroup lowered VolitionRX to a “hold” rating in a research report on Monday. Finally, HC Wainwright lowered their price objective on VolitionRX from $1.50 to $1.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $2.33.

Institutional Investors Weigh In On VolitionRX

Hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC grew its position in VolitionRX by 166.6% in the 4th quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock valued at $28,000 after buying an additional 67,848 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of VolitionRX during the 4th quarter worth about $34,000. Jane Street Group LLC bought a new stake in shares of VolitionRX during the 4th quarter worth about $28,000. Geode Capital Management LLC lifted its stake in shares of VolitionRX by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after acquiring an additional 85,816 shares during the period. Finally, Armistice Capital LLC boosted its holdings in shares of VolitionRX by 10.4% in the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock valued at $6,367,000 after acquiring an additional 887,351 shares in the last quarter. 8.09% of the stock is currently owned by institutional investors.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.